Publications by authors named "Steven Weitman"

Claim this Profile
S
Single-Cell Proteomic Profiling Identifies Combined AXL and JAK1 Inhibition as a Novel Therapeutic Strategy for Lung Cancer.
Josephine A Taverna, Chia-Nung Hung, Daniel T DeArmond, Meizhen Chen, Chun-Lin Lin, Steven Weitman

Cancer Res· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma.
Kevin R Kelly, Jonathan W Friedberg, Steven I Park, Kevin McDonagh, John Hayslip, Steven Weitman

Clin Cancer Res· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study.
Anastasios Stathis, Ian W Flinn, Sumit Madan, Kami Maddocks, Arnold Freedman, Steven Weitman

Invest New Drugs· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined venetoclax and alvocidib in acute myeloid leukemia.
James Bogenberger, Clifford Whatcott, Nanna Hansen, Devora Delman, Chang-Xin Shi, Steven Weitman

Oncotarget· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risks and benefits of phase I liver dysfunction studies: should patients with severe liver dysfunction be included in these trials?
Christos Fountzilas, Selena Stuart, Brian Hernandez, Elizabeth Bowhay-Carnes, Joel Michalek, Steven Weitman

Invest New Drugs· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Pharmacodynamics of the PDE4 Inhibitor Roflumilast in Advanced B-cell Malignancies.
Kevin Kelly, Alex Mejia, Avvaru N Suhasini, An-Ping Lin, John Kuhn, Steven Weitman

Clin Cancer Res· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 study evaluating the safety and pharmacokinetics of pralatrexate in relapsed/refractory advanced solid tumors and lymphoma patients with mild, moderate, and severe renal impairment.
Kevin R Kelly, Nashat Gabrail, Steven Weitman, John Sarantopoulos, Anthony J Olszanski

Cancer Chemother Pharmacol· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metformin for Reducing Racial/Ethnic Difference in Prostate Cancer Incidence for Men with Type II Diabetes.
Chen-Pin Wang, Donna M Lehman, Yui-Wing F Lam, John G Kuhn, Devalingam Mahalingam, Steven Weitman

Cancer Prev Res (Phila)· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of intravenously administered ATI-1123, a liposomal docetaxel formulation in patients with advanced solid tumors.
Devalingam Mahalingam, John J Nemunaitis, Laeeq Malik, John Sarantopoulos, Steven Weitman

Cancer Chemother Pharmacol· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Eligibility of patients with renal impairment for Phase I trials: Time for a rethink?
Laeeq Malik, Alex Mejia, Steven Weitman

Eur J Cancer· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predicting success in regulatory approval from Phase I results.
Laeeq Malik, Alex Mejia, Helen Parsons, Benjamin Ehler, Devalingam Mahalingam, Steven Weitman

Cancer Chemother Pharmacol· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Should we move beyond VEGF inhibition in metastatic colorectal cancer? Lessons from early phase clinical trials.
Sukeshi R Patel, Anand B Karnad, Norma S Ketchum, Brad H Pollock, John Sarantopoulos, Steven Weitman

J Gastrointest Oncol· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Promoting Factors and Barriers to Participation in Early Phase Clinical Trials: Patients Perspectives.
Patricia Chalela, Lucina Suarez, Edgar Muñoz, Kipling J Gallion, Brad H Pollock, Steven D Weitman

J Community Med Health Educ· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-cell analysis of circulating tumor cells identifies cumulative expression patterns of EMT-related genes in metastatic prostate cancer.
Chun-Liang Chen, Devalingam Mahalingam, Pawel Osmulski, Rohit R Jadhav, Chiou-Miin Wang, Steven D Weitman

Prostate· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early Phase Clinical Trials: Referral Barriers and Promoters among Physicians.
Amelie G Ramirez, Patricia Chalela, Lucina Suarez, Edgar Muñoz, Brad H Pollock, Steven D Weitman

J Community Med Health Educ· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia.
Sima Jeha, Paul S Gaynon, Bassem I Razzouk, Janet Franklin, Richard Kadota, Steven Weitman

J Clin Oncol· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The angiogenesis inhibitor NM-3 is active against human NSCLC xenografts alone and in combination with docetaxel.
Naoki Agata, Hiroko Nogi, Michael Bamberg, Michael Milhollen, Minying Pu, Steven Weitman

Cancer Chemother Pharmacol· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I trial and pharmacokinetic study of raltitrexed in children with recurrent or refractory leukemia: a pediatric oncology group study.
Terzah M Horton, Susan M Blaney, Anne-Marie Langevin, John Kuhn, Barton Kamen, Steven Weitman

Clin Cancer Res· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activity of irofulven against human pancreatic carcinoma cell lines in vitro and in vivo.
Emily S Van Laar, Stephanie Roth, Steven Weitman, John R MacDonald, Stephen J Waters

Anticancer Res· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antitumor activity of irofulven monotherapy and in combination with mitoxantrone or docetaxel against human prostate cancer models.
Emily S Van Laar, Steven Weitman, John R MacDonald, Stephen J Waters

Prostate· April 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anemia and hepatosplenomegaly as presenting features in a child with rickets and secondary myelofibrosis.
Barbara A Gruner, Thomas S DeNapoli, Said Elshihabi, Howard A Britton, Anne-Marie Langevin, Steven D Weitman

J Pediatr Hematol Oncol· October 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I trial of rebeccamycin analog (NSC #655649) in children with refractory solid tumors: a pediatric oncology group study.
Anne-Marie Langevin, Steven D Weitman, John G Kuhn, Susan T Weintraub, Sylvain Baruchel

J Pediatr Hematol Oncol· July 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AMD473 (ZD0473) exhibits marked in vitro anticancer activity in human tumor specimens taken directly from patients.
Leticia Medina-Gundrum, Cesario Cerna, Lionel R Gomez, Michael Yochmowitz, Steven Weitman

Anticancer Drugs· April 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Direct Raman imaging techniques for study of the subcellular distribution of a drug.
Jian Ling, Steven D Weitman, Michael A Miller, Rodney V Moore, Alan C Bovik

Appl Opt· October 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical antitumor activity and pharmacokinetics of methyl-2-benzimidazolecarbamate (FB642).
Desirée Hao, Jinee D Rizzo, Stephanie Stringer, Rodney V Moore, Jennifer Marty, Steven D Weitman

Invest New Drugs· August 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis